134 related articles for article (PubMed ID: 11402259)
1. Ziprasidone (Geodon) for schizophrenia.
Med Lett Drugs Ther; 2001 Jun; 43(1106):51-2. PubMed ID: 11402259
[No Abstract] [Full Text] [Related]
2. Focus on ziprasidone.
Green B
Curr Med Res Opin; 2001; 17(2):146-50. PubMed ID: 11759185
[TBL] [Abstract][Full Text] [Related]
3. Introduction. Ziprasidone in schizophrenia: from acute treatment to long-term management.
Kane JM
J Clin Psychiatry; 2003; 64 Suppl 19():3-5. PubMed ID: 14728083
[No Abstract] [Full Text] [Related]
4. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
Stahl SM; Shayegan DK
J Clin Psychiatry; 2003; 64 Suppl 19():6-12. PubMed ID: 14728084
[TBL] [Abstract][Full Text] [Related]
5. Maintaining symptom control: review of ziprasidone long-term efficacy data.
Schooler NR
J Clin Psychiatry; 2003; 64 Suppl 19():26-32. PubMed ID: 14728087
[TBL] [Abstract][Full Text] [Related]
6. Three cases of schizophrenia showing improvement after switching to blonanserin.
Kurotaki N; Nobata H; Nonaka S; Nishihara K; Ozawa H
Psychiatry Clin Neurosci; 2011 Jun; 65(4):396-7. PubMed ID: 21682816
[No Abstract] [Full Text] [Related]
7. Tolerability of ziprasidone: an expanding perspective.
Daniel DG
J Clin Psychiatry; 2003; 64 Suppl 19():40-9. PubMed ID: 14728089
[TBL] [Abstract][Full Text] [Related]
8. Ziprasidone: a new atypical antipsychotic.
Keck PE; McElroy SL; Arnold LM
Expert Opin Pharmacother; 2001 Jun; 2(6):1033-42. PubMed ID: 11585006
[TBL] [Abstract][Full Text] [Related]
9. Ziprasidone: a novel psychotropic with unique properties.
Ballas C; Yang C; O'Reardon J; Ballas P; Baldassano C
Expert Rev Neurother; 2004 Mar; 4(2):179-86. PubMed ID: 15853558
[TBL] [Abstract][Full Text] [Related]
10. From clinical research to clinical practice: a 4-year review of ziprasidone.
Nemeroff CB; Lieberman JA; Weiden PJ; Harvey PD; Newcomer JW; Schatzberg AF; Kilts CD; Daniel DG
CNS Spectr; 2005 Nov; 10(11 Suppl 17):1-20. PubMed ID: 16381088
[TBL] [Abstract][Full Text] [Related]
11. Ziprasidone and cognition: the evolving story.
Harvey PD
J Clin Psychiatry; 2003; 64 Suppl 19():33-9. PubMed ID: 14728088
[TBL] [Abstract][Full Text] [Related]
12. [Ziprasidone and dementia].
Aakhus E
Tidsskr Nor Laegeforen; 2004 Aug; 124(16):2155-6; author reply 2155-6. PubMed ID: 15334150
[No Abstract] [Full Text] [Related]
13. Strategies for successful clinical management of schizophrenia with ziprasidone.
Fagiolini A; Cañas F; Gallhofer B; Larmo I; Levy P; Montes JM; Papageorgiou G; Zink M; Rossi A
Expert Opin Pharmacother; 2010 Sep; 11(13):2199-220. PubMed ID: 20658947
[TBL] [Abstract][Full Text] [Related]
14. Ziprasidone: comprehensive overview and clinical use of a novel antipsychotic.
Daniel DG; Copeland LF
Expert Opin Investig Drugs; 2000 Apr; 9(4):819-28. PubMed ID: 11060712
[TBL] [Abstract][Full Text] [Related]
15. Ziprasidone treatment of delirium.
Leso L; Schwartz TL
Psychosomatics; 2002; 43(1):61-2. PubMed ID: 11927760
[No Abstract] [Full Text] [Related]
16. Iloperidone for schizophrenia.
Rado J; Janicak PG
Expert Opin Pharmacother; 2010 Aug; 11(12):2087-93. PubMed ID: 20586713
[TBL] [Abstract][Full Text] [Related]
17. [Ziprasidone. A new second-generation antipsychotic agent].
Lublin HK
Ugeskr Laeger; 2004 Mar; 166(14):1334-9. PubMed ID: 15101124
[No Abstract] [Full Text] [Related]
18. Combination of ziprasidone and clozapine in treatment-resistant schizophrenia.
Zink M; Mase E; Dressing H
Hum Psychopharmacol; 2004 Jun; 19(4):271-3. PubMed ID: 15181656
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of the prevention of relapse of schizophrenia in the longitudinal study Ziprasidone Extended Use in Schizophrenia (ZEUS).
Bernardo M; Azanza JR; Rubio-Terrés C; Rejas J
Actas Esp Psiquiatr; 2007; 35(4):259-62. PubMed ID: 17592789
[TBL] [Abstract][Full Text] [Related]
20. The lack of effect of ziprasidone on platelet serotonin concentration in schizophrenic patients.
Sagud M; Nikolac M; Mihaljevic-Peles A; Nedic G; Vuksan Cusa B; Mustapic M; Jakovljevic M; Muck-Seler D; Pivac N
Psychopharmacology (Berl); 2012 Feb; 219(4):1179-81. PubMed ID: 21989808
[No Abstract] [Full Text] [Related]
[Next] [New Search]
